Michael Kuo
Pain Medicine · Leesburg, VANPI 1427057686
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $686 and has fallen 74.9% since, to $172 in 2025.
Across 195 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$712
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$427
- Scilex Pharmaceuticals Inc.$380
- Collegium Pharmaceutical, Inc.$370
- Lilly USA, LLC$177
- Supernus Pharmaceuticals, Inc.$151
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $712 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $427 |
| Scilex Pharmaceuticals Inc. | 27 | $380 |
| Collegium Pharmaceutical, Inc. | 19 | $370 |
| Lilly USA, LLC | 9 | $177 |
| Supernus Pharmaceuticals, Inc. | 8 | $151 |
| Biodelivery Sciences International, Inc. | 7 | $127 |
| Pfizer | 6 | $121 |
| IBSA Pharma Inc. | 5 | $93 |
| Zyla Life Sciences, Inc. | 7 | $90 |
| Boston Scientific | 5 | $83 |
| Ferring Pharmaceuticals Inc. | 4 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $58 |
| Amgen | 2 | $53 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| Pacira Therapeutics, Inc. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 1 | $25 |
| Fidia Pharma USA Inc. | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Vertex | 1 | $22 |
| Novartis | 1 | $22 |
| Bioventus LLC | 1 | $19 |
| GRT US Holding, Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Averitas Pharma Inc. | 1 | $16 |
| Abbott | 1 | $13 |
How this compares
$3,331 in reported general payments places this provider in the 65th percentile of 150 pain medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 12 | $77,636 |
| RelistorMethylnaltrexone Bromide | 15 | $34,940 |
| OxycontinOxycodone Hcl | 50 | $26,673 |
| Hysingla ErHydrocodone Bitartrate | 14 | $13,687 |
| Gabapentin | 491 | $10,350 |
| BelbucaBuprenorphine Hcl | 13 | $9,401 |
| Lidocaine | 34 | $5,861 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 240 | $5,156 |
| Oxycodone Hcl | 188 | $4,928 |
| Fentanyl | 43 | $4,454 |
| Pregabalin | 84 | $3,696 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 213 | $2,924 |
| Tramadol Hcl | 384 | $2,681 |
| Celecoxib | 58 | $1,835 |
| Duloxetine Hcl | 64 | $1,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $427 | $34,94015 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $370 | $9,40113 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $17 | $34314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 150 pain medicine providers in Virginia.
Other pain medicine in Leesburg
- Chirag SanghviLeesburg$2K
- Chheany UngRoanoke$198K
- Daniel KendallMc Lean$100K
- Steven GershonVirginia Beach$78K
- Jared DavisFishersville$45K
- Nameer HaiderWoodbridge$36K
- Lynn KohanCharlottesville$30K
- George BaylorSalem$24K
- Jasmit BrarLansdowne$18K
- Christina ShinCharlottesville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.